Qiagen N.V. Common Shares (QGEN)
QGEN moved a median of +0.05% 30 minutes after news, and -0.03% by the close. How QGEN actually reacts to news — the realized, point-in-time move the market made, measured across 266 labeled events over the last three years with zero look-ahead.
QGEN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 262 |
| 30-min | +0.05% | 53% | 265 |
| 60-min | +0.05% | 54% | 265 |
| to close | -0.03% | 49% | 264 |
| Middle 50% of QGEN reactions | -0.38% to +0.37% |
|---|---|
| Median reaction (30-min) | +0.05% |
| Measured reactions | 266 |
Half of all Qiagen N.V. Common Shares news events land between -0.38% and +0.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How QGEN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 26 | -0.12% | 46% | +0.20% |
| Analyst downgrades | 28 | -0.64% | 43% | -0.36% |
| Coverage initiations | 16 | +0.24% | 75% | +1.17% |
| Rating reiterations | 45 | 0.00% | 44% | +0.04% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how QGEN ranks against every other measured name →
That’s how QGEN usually reacts — get an email when it moves on news →Email me when QGEN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to QGEN's baseline. Nothing else.
Recent QGEN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Press release | Business Wire | +0.83% | -0.59% | |
| QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery | Press release | Business Wire | -0.22% | -1.80% | |
| QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel | Press release | Business Wire | +0.87% | +0.87% | |
| QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation | Press release | Business Wire | -0.18% | -1.23% | |
| QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board | Press release | Business Wire | +0.23% | +1.43% | |
| Form 6-K QIAGEN N.V. For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | +0.12% | +1.12% | |
| QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction | Press release | Business Wire | +0.57% | -1.06% | |
| QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer | Press release | Business Wire | — | -4.48% | |
| Form 6-K QIAGEN N.V. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.49% | -0.49% | |
| QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook | Press release | Business Wire | -0.87% | -1.51% | |
| QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak | Press release | Business Wire | +0.46% | +0.05% | |
| QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast | Press release | Business Wire | +0.56% | -0.91% | |
| QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe | Press release | Business Wire | +0.56% | -0.91% | |
| QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma | Press release | Business Wire | -0.05% | +0.19% | |
| Form SD QIAGEN N.V. | SEC filing · Form SD | SEC EDGAR | -0.54% | +0.08% | |
| QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak | Press release | Business Wire | +0.04% | -0.08% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Qiagen N.V. (QGEN) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.17% | +0.51% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Qiagen N.V. (QGEN) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.09% | -0.12% | |
| QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows | Press release | Business Wire | -0.90% | -0.03% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Qiagen N.V. (QGEN) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.12% | -1.01% | |
| QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Press release | Business Wire | -1.49% | +2.27% | |
| Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.39% | +1.38% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Qiagen N.V. (QGEN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.12% | -0.54% | |
| Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.06% | -1.74% | |
| Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.07% | -0.68% | |
| QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting | Press release | Business Wire | -0.45% | +0.72% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Qiagen N.V. (QGEN) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.09% | -1.75% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Qiagen N.V. (QGEN) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.69% | -1.78% | |
| Form 6-K QIAGEN N.V. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.05% | |
| QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing | Press release | Business Wire | +0.54% | -0.09% | |
| QIAGEN Reports Full Results for Q1 2026 | Press release | Business Wire | +0.54% | -0.09% | |
| Form 6-K QIAGEN N.V. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.83% | +1.48% | |
| QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook | Press release | Business Wire | -1.05% | -3.10% | |
| QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026 | Press release | Business Wire | -0.17% | -1.15% | |
| QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel | Press release | Business Wire | +0.33% | -0.95% | |
| Form 20-F QIAGEN N.V. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.87% | -0.99% | |
| Form IRANNOTICE QIAGEN N.V. | SEC filing · Form IRANNOTICE | SEC EDGAR | -0.87% | -0.99% | |
| Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | Press release | Business Wire | -0.87% | -0.99% | |
| QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention | Press release | Business Wire | -0.87% | -0.99% | |
| QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System | Press release | Business Wire | -0.80% | -3.40% | |
| Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery | Press release | Business Wire | -0.20% | -0.96% | |
| Form 6-K QIAGEN N.V. For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.84% | -0.23% | |
| QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars | Press release | Business Wire | +0.92% | +2.30% | |
| QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026 | Press release | Business Wire | -0.47% | -0.94% | |
| QIAGEN Appoints Mark Stevenson to Supervisory Board | Press release | Business Wire | +0.72% | -0.31% | |
| QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast | Press release | Business Wire | -1.04% | +18.64% | |
| QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth | Press release | Business Wire | -0.42% | -2.72% | |
| Form 6-K QIAGEN N.V. For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.33% | +1.30% | |
| QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Press release | Business Wire | +0.07% | -0.40% | |
| QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025 | Press release | Business Wire | +0.39% | -0.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the QGEN section they belong to.
Where else QGEN is measured.
QGEN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Galapagos NV - American Depositary Shares (GLPG) | 267 | -0.05% | 44% |
| Eyenovia, Inc. (EYEN) | 266 | -0.95% | 38% |
| 22nd Century Group, Inc (XXII) | 266 | -1.87% | 30% |
| Cellectar Biosciences, Inc. (CLRB) | 265 | +0.27% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Qiagen N.V. Common Shares's median reaction calculated?
Every labeled QGEN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 266 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of QGEN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does QGEN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.